Regulatory/Compliance Filing
Bajaj Healthcare Allots ESOP Shares
Bajaj Healthcare allotted 26,710 equity shares under its Employee Stock Option Scheme 2024 after exercise of vested options at ₹5 per share.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
4
Neutral
7
Bullish
3
Bearish
23
Neutral
7
Bullish
16
Bearish
19
Neutral
0
Bullish
13
Bearish
19
Neutral
0
Bullish
13
Bearish
19
Neutral
0
Bullish
13
Bearish
19
Neutral
0
Bullish
13
Investor Presentation
Q1 FY27
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY24
Investor Presentation
Q4 FY22
Investor Presentation
Q1 FY21
Bajaj Healthcare Ltd (BAJAJHCARE) is currently trading at 319.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bajaj Healthcare Limited manufactures and exports APIs, intermediates, finished dosage forms, and nutraceuticals through vertically integrated facilities across Gujarat and Maharashtra, serving domestic and international pharmaceutical markets. Its operating model increasingly combines API production with formulation development, CDMO partnerships, specialty products, and planned backward integration in oncology and peptide manufacturing. Q2 FY27 revenue increased 18.9% year-on-year to INR175.9 crore, while profit after tax rose 26.9% to INR14.1 crore. The strongest momentum came from formulations, which grew nearly 82%, and API exports, which expanded 28.5%, offsetting moderation in domestic APIs and demonstrating the benefits of a more diversified product mix. The company has moved beyond conventional API growth by becoming the first Indian company to receive DCGI approval for Cenobamate API tablets in six strengths. Commercial launch through eight partners began in September, and repeat orders provide an early indication of market acceptance, although management has not quantified future revenue. Bajaj Healthcare Limited is building a multi-year specialty platform around peptides, oncology, regulatory filings, and formulations. Its peptide plant will have 250 kg annual capacity, six peptide APIs are already developed at pilot scale, and management expects the facility to generate INR70–100 crore in its first year before potentially reaching approximately INR300 crore cumulatively in the following year. Management targets revenue of INR900–1,000 crore and EBITDA margins of 18–21% by FY29. Achieving this ambition depends on timely commissioning, regulatory approvals, customer qualification, international commercialisation, and successful integration of new senior talent, while current working capital remains elevated because of inventory maintained amid West Asia-related supply-chain uncertainty.
Over the past 52 weeks, Bajaj Healthcare Ltd has traded between a low of ₹272.45 and a high of ₹468.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bajaj Healthcare Ltd has a market capitalization of approximately 1,077.71. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bajaj Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,077.71 Cr, Bajaj Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bajaj Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bajaj Healthcare Ltd is 18.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bajaj Healthcare reported standalone net profit of ₹14.09 crore for Q2 FY27, up 26.8% from ₹11.11 crore in Q2 FY26.
The list includes HDFC Bank, ICICI Bank, AXIS Bank, Yes Bank, IDBI Bank, Central Bank of India, Punjab & Sind Bank, India Cements, Ixigo, and others, totalling 18 companies.
It received a recommendation from the Subject Expert Committee (SEC) under CDSCO to manufacture and market Cenobamate tablets in six strengths.
The stock moved up after the company said the CDSCO’s Subject Expert Committee recommended approval to manufacture and market Cenobamate tablets.

Pharmaceuticals & Biotechnology
Pharmaceuticals
1,078 Cr
High Risk
18.52
39.00
0.97
1.93
468.00
272.45
Sales CAGR
Profit CAGR
ROE
ROCE